Tumor News and Research

RSS

CT-guided biopsy: An alternative method for patients with pancreatic masses

It is reasonable to obtain a histological diagnosis before treating patients who have pancreatic masses and are unsuitable or unwilling to undergo surgery. As the pancreas is a deep seated organ surrounded by other vital structures, it is a challenge for the physician to obtain an adequate specimen for histological examination.

17 Jan 2010

Multimmune GmbH and Boulder Diagnostics partner to develop HSP70 lateral flow point of care test

Multimmune GmbH and Boulder Diagnostics Inc. announce today the joint development of an HSP70 lateral flow point of care test. Multimmune has discovered that many tumor types display the heat shock protein 70 (Hsp70) on the cell surface.

13 Jan 2010

Researchers discover 93-gene signature associated with EGFR mutations in lung cancer tumors

Epidermal growth factor receptor (EGFR) is a validated therapeutic target for non-small cell lung cancer. Researchers have now discovered a 93-gene signature that is associated with the presence of EGFR mutations in tumors from lung cancer patients and is a favorable prognostic marker in patients with early stage lung cancer.

13 Jan 2010

Research shows missing, mutated genes occur simultaneously in unique set of pediatric brain tumors

Brain cancer is the leading cause of cancer death in children. Now a more accurate diagnosis of childhood brain cancers may soon be possible, according to researchers at Huntsman Cancer Institute (HCI) at the University of Utah. The information is published online today in the journal Cancer Research.

13 Jan 2010

Retreating with gefitinib may benefit non-small cell lung cancer patients

Patients with non-small cell lung cancer in whom treatment with gefitinib is ineffective often have limited options, but results of a new study suggest that retreating patients with the same drug could have a beneficial effect.

13 Jan 2010

Three tumor microRNAs may help identify chemoresistance in small cell lung cancer patients

At least three tumor microRNAs appear to predict when first-line chemotherapy will prove ineffective in some patients with small cell lung cancer, according to data presented at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, held Jan. 11-14, 2010.

13 Jan 2010

Synta Pharmaceuticals presents preclinical results of STA-9090 at AACR-IASLC Joint Conference

Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.

13 Jan 2010

Research reveals how cancers shield themselves from immune attack

Melanoma, if not detected in its early stages, transforms into a highly deadly, treatment-resistant cancer. Although the immune system initially responds to melanoma and mounts anti-tumor attacks, these assaults are generally ineffective, allowing more advanced melanomas to win the battle and spread beyond the primary site.

13 Jan 2010

Spectrum Pharmaceuticals achieves its enrollment target in second of two apaziquone Phase 3 trials

Spectrum Pharmaceuticals today announced that the second of two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target. The two trials enrolled more than 1600 patients with non-muscle invasive bladder cancer. As per the collaboration agreement with Allergan, a $1.5 million milestone payment will be paid to Spectrum Pharmaceuticals.

13 Jan 2010

Bevacizumab drug shows promise to slow tumor growth in lung cancer patients

Phase II study results of the agent ASA404 showed promise in patients with either squamous or non-squamous non-small cell lung cancer (NSCLC).

13 Jan 2010

TD2 and COTI work together to obtain approval of clinical trials for COTI-2

TGen Drug Development (TD2) and Critical Outcome Technologies Inc. (COTI) (TSXV:COT) announced today that they will work together to obtain approval of clinical trials for a promising new anti-cancer drug called COTI-2.

12 Jan 2010

Preliminary results from Nektar Therapeutics' NKTR-102 Phase 2 study in platinum-resistant ovarian cancer

Nektar Therapeutics today announced preliminary results from the first stage of a two-stage Phase 2 clinical study evaluating NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients enrolled with platinum-resistant disease were evaluable for the primary endpoint of overall response rate using Gynecologic Cancer InterGroup (GCIG) criteria, i.e., a combination of response by tumor imaging

12 Jan 2010

Abraxis Bioscience awards John Wayne Cancer Institute $1M grant for identifying new cancer biomarkers

A $1 million grant from Abraxis Bioscience, Inc. to a world-famous research laboratory at John Wayne Cancer Institute at Saint John’s Health Center could help save lives of cancer patients by helping doctors more rapidly assess whether a treatment is working or not.

12 Jan 2010

Enrollment complete in Dune Medical Devices' MarginProbe pivotal clinical trial

Dune Medical Devices today announced the completion of patient enrollment in the MarginProbe™ pivotal clinical trial. The MarginProbe procedure provides surgeons with real-time detection of cancer at the edges of the tissue removed during breast conservation surgery (BCS), which is the only way to ensure the complete removal of the tumor from the breast. The randomized, controlled trial includes 664 women who underwent BCS at one of 21 leading medical facilities, with 18 in the US and three in Israel.

12 Jan 2010

Older patients with acute myeloid leukemia may benefit from decitabine drug

Older patients with acute myeloid leukemia (AML) might benefit from a drug that reactivates genes that cancer cells turn off, according to research at Washington University School of Medicine in St. Louis and collaborating institutions.

12 Jan 2010

Ubiquitin-conjugating enzyme promotes chromosome missegregation and tumor formation

A ubiquitin-conjugating enzyme that regulates the cell cycle promotes chromosome missegregation and tumor formation, according to van Ree et al. in the January 11 issue of the Journal of Cell Biology (www.jcb.org).

12 Jan 2010

Obese white men with diabetes face worse outcomes following radical prostatectomy

Obese white men who have both diabetes and prostate cancer have significantly worse outcomes following radical prostatectomy than do men without diabetes who undergo the same procedure, according to research from Duke University Medical Center appearing in Cancer Epidemiology, Biomarkers & Prevention

12 Jan 2010

Multigene test results impact physicians and patients' decisions on breast cancer therapy

A 21-gene test that predicts whether early stage breast cancer patients will benefit from chemotherapy is having a big impact on treatment decisions by patients and doctors alike.

12 Jan 2010

Neoprobe submits IND amendment to FDA for RIGScan CR radiopharmaceutical

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, announced today that it has submitted an investigational new drug (IND) amendment to the United States Food and Drug Administration (FDA) which includes the design of a proposed Phase 3 clinical trial of Neoprobe’s RIGScan® CR radiopharmaceutical.

12 Jan 2010

YM BioSciences announces results of cancer antibody-radionuclide conjugate development collaboration

YM BioSciences Inc. today announced results of a collaboration with researchers at the University of Toronto for the development of highly potent antibody-radionuclide conjugates for use in the treatment of cancer. The approach has successfully concluded its first series of proof-of-principle experiments establishing promise for future development and application.

12 Jan 2010

Tumor News and Research

CT-guided biopsy: An alternative method for patients with pancreatic masses

Multimmune GmbH and Boulder Diagnostics partner to develop HSP70 lateral flow point of care test

Researchers discover 93-gene signature associated with EGFR mutations in lung cancer tumors

Research shows missing, mutated genes occur simultaneously in unique set of pediatric brain tumors

Retreating with gefitinib may benefit non-small cell lung cancer patients

Three tumor microRNAs may help identify chemoresistance in small cell lung cancer patients

Synta Pharmaceuticals presents preclinical results of STA-9090 at AACR-IASLC Joint Conference

Research reveals how cancers shield themselves from immune attack

Spectrum Pharmaceuticals achieves its enrollment target in second of two apaziquone Phase 3 trials

Bevacizumab drug shows promise to slow tumor growth in lung cancer patients

TD2 and COTI work together to obtain approval of clinical trials for COTI-2

Preliminary results from Nektar Therapeutics' NKTR-102 Phase 2 study in platinum-resistant ovarian cancer

Abraxis Bioscience awards John Wayne Cancer Institute $1M grant for identifying new cancer biomarkers

Enrollment complete in Dune Medical Devices' MarginProbe pivotal clinical trial

Older patients with acute myeloid leukemia may benefit from decitabine drug

Ubiquitin-conjugating enzyme promotes chromosome missegregation and tumor formation

Obese white men with diabetes face worse outcomes following radical prostatectomy

Multigene test results impact physicians and patients' decisions on breast cancer therapy

Neoprobe submits IND amendment to FDA for RIGScan CR radiopharmaceutical

YM BioSciences announces results of cancer antibody-radionuclide conjugate development collaboration

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News